South Korea’s Ministry of Health and Welfare is bolstering regulatory support for the entire lifecycle of rare disease treatment development, from initial research through to market authorization, in an effort to accelerate access to therapies for conditions affecting a limited number of patients.
The move, detailed in a recent briefing to the press, acknowledges that scientific difficulty is not the sole impediment to rare disease drug development. The limited patient populations and challenges in securing sufficient clinical data often lead to delays that directly translate to lost treatment opportunities, according to officials.
The Ministry’s revised approach aims to transform the regulatory agency from a final gatekeeper to a development partner, offering guidance and support at each stage. This includes early-stage regulatory consultations, designation programs, expedited reviews, and streamlined authorization processes. The Korea Health Industry Development Institute (KHIDI) is playing a key role in coordinating these efforts.
“The biggest variable in rare disease treatment development isn’t just scientific difficulty,” explained Park Mi-sun, a project manager at KHIDI’s K-Health Future Promotion Division. “Development delays, in an environment where patient numbers are small and clinical data is difficult to obtain, directly equate to lost chances for treatment.”
The National Institute for Health (NIH) in South Korea is as well actively involved, focusing on clinical and genomic analysis of rare diseases to accumulate Korean-specific genetic information and develop clinical practice guidelines for secondary findings. The NIH is working to secure information on variants of uncertain significance (VUS) in undiagnosed rare disease cases, according to a statement on its website.
The initiative comes as artificial intelligence (AI) firms are increasingly focusing on predicting clinical success in rare disease pipelines. IDBain, an AI-driven drug development analytics company, recently released analysis suggesting a high probability of success for NDC-011, a complex drug developed by Doctor Noah Biotech for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. IDBain’s system, which combines vector-model analysis, a bio-specific large language model, and a hybrid-LLM, is designed to predict clinical success and FDA approval with 80-90% accuracy, focusing specifically on Phase 2 clinical trials – a stage known for high failure rates in rare disease development.
Though, applying AI to rare disease pipelines has historically been challenging due to the limited data available. The focus on Phase 2 trials reflects the critical need to identify promising candidates early in the development process.
The Ministry of Food and Drug Safety (MFDS) is emphasizing a “whole-cycle regulatory system,” supporting development from the initial stages through to authorization. This represents a shift from simply reviewing requirements at the approval stage to actively engaging in the development process itself.
The MFDS has not yet announced a specific timeline for the full implementation of the novel regulatory framework, and no public comment period has been scheduled.
